(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)~
`
`(19) World Intellectual Property
`~~
`Organization
`International Bureau
`
`(43) International Publication Date
`4 February 2016 (04.02.2016) Wi
`
`POIPCT
`
`ANY
`
`(10) International Publication Number
`WO 2016/019237 A2
`
`Designated States (unless otherwise indicated, for every
`kind 6 national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
`DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
`HN, HR, HU,ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
`KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
`MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
`PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
`SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
`TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
`
`Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
`TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
`TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
`DK, EE, ES, FI, FR, GB, GR, HR, HU,IE, IS, IT, LT, LU,
`LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
`SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
`GW, KM, ML, MR, NE, SN, TD, TG).
`
`(31)
`
`International Patent Classification:
`A6I1K 31/53 (2006.01)
`A61K 31/522 (2006.01)
`
`(81)
`
`(21)
`
`International Application Number:
`
`PCT/US20 15/043 102
`
`(22)
`
`International Filing Date:
`
`Filing Language:
`
`Publication Language:
`
`31 July 2015 (31 .07.2015)
`
`English
`
`English
`
`Priority Data:
`62/03 1,658
`
`31 July 2014 (31.07.2014)
`
`(84)
`
`US
`
`(25)
`
`(26)
`
`(30)
`
`(71)
`
`(72)
`
`Applicant: PHARMACYCLICS LLC [US/US]; 995 E.
`Arques Avenue, Sunnyvale, CA 94085-4521 (US).
`
`Inventors: CHEN, Wei; 1668 Walden Court, Fremont,
`CA 94539 (US). WANG, Longcheng; 4294 Wilkie Way -
`Apt. L, Palo Alto, CA 94306 (US). JIA, Zhaozhong, J.;
`3416 Leafwood Court, San Mateo, CA 94403
`(US).
`PALMER, James, T.; 3-100 Parker Street, Templestowe,
`VIC 3106 (AU).
`
`Published:
`
`(74)
`
`Agent: JACKSON, David, A.; Klauber & Jackson L.L.C.,
`25 Fast Spring Valley Avenue - Suite 160, Maywood, NJ
`07607 (US).
`
`without international search report and to be republished
`upon receipt f that report (Rule 48.2(g))
`
`(54)
`
`Title: INHIBITORS OF BRUTON'S TYROSINE KINASE
`
`(57) Abstract: Described herein are cyano containing heteroaryl compounds as kinase inhibitors. Methods for synthesizing such in -
`hibitors, and methods for using such inhibitors in the treatment of diseases described.
`
`
`
`wo2°16/6192372|IMTINNNNAITOTT
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`INHIBITORS OF BRUTON'S TYROSINE KINASE
`
`CROSS-REFERENCE TO RELATED APPLICATION
`
`[0001] This application claims the benefit of U.S. Provisional Application No. 62/03 1,658, filed July 31,
`
`2014, which is incorporated herein by reference in its entirely.
`
`FIELD OF THE INVENTION
`
`[0002] Described herein are compounds, methods of making such compounds, pharmaceutical
`
`compositions and medicaments containing such compounds, and methods of using such compounds and
`
`compositions to inhibit the activity of tyrosine kinases.
`
`BACKGROUND OF THE INVENTION
`
`[0003] Bruton's tyrosine kinase (Btk), a member of the Tec family of non-receptor tyrosine kinases, is a
`
`key signaling enzyme expressed in all hematopoietic cells types except T lymphocytes and natural killer
`
`cells. Btk plays an essential role in the B-cell signaling pathway linking cell surface B-cell receptor (BCR)
`
`stimulation to downstream intracellular responses.
`
`[0004] Btk is akey regulator of B-cell development, activation, signaling, and survival (Kurosaki, Curr
`
`Op Imm, 2000, 276-281; Schaefter and Schwartzberg, Curr Op Imm 2000, 282-288). In addition, Btk
`
`plays arole in anumber of other hematopoetic cell signaling pathways, e.g., Toll like receptor (TLR) and
`
`cytokine receptor-mediated TNF-a production in macrophages, IgE receptor (FcepsilonRI) signaling in
`
`Mastcells, inhibition of Fas‘/APO-1 apoptotic signaling in B-lineage lymphoid cells, and collagen-
`
`stimulated platelet aggregation. See, e.g., C. A. Jeffries, et al., (2003), Journal o Biological Chemistry
`
`278:26258-26264; N.J. Horwood, et al,
`
`(2003), The Journal o Experimental Medicine 197: 1603-161 1;
`
`Iwaki et al. (2005), Journal o Biological Chemistry 280(48):40261-40270; Vassilev et al. (1999), Journal
`
`& Biological Chemistry 274(3): 1646-1656, and Quek et al. (1998), Current Biology 8(20): 1137-1 140.
`
`SUMMARY OF THE INVENTION
`
`[0005] Described herein are inhibitors of Bruton's tyrosine kinase (Btk). Also described herein are
`irreversible inhibitors of Btk. Also described herein are reversible inhibitors of Btk.
`
`[0006] Further described are irreversible inhibitors of Btk that form a covalent bond with a cysteine
`
`residue on Btk. Further described herein are irreversible inhibitors of other tyrosine kinases, wherein the
`
`other tyrosine kinases share homology with Btk by having a cysteine residue (including a Cys 481
`
`residue) that can form a covalent bond with the irreversible inhibitor (such tyrosine kinases, are referred.
`
`herein as "Btk tyrosine kinase cysteine homologs").
`
`[0007] Further described are irreversible inhibitors of Btk that form a covalent bond with a serine residue
`
`on C4818 mutated Btk. Specifically described are irreversible inhibitors of Btk that form a covalent bond
`
`with a serme481 residue on C481 S mutated Btk (Woyach, ef ai. Resistance mechanisms for the Bruton's
`
`tyrosine kinase inhibitor Ibrutimb, N Engl J Med. 2014, 12;370(24):2286-94). Further described herein are
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`irreversible inhibitors of other tyrosine kinases, wherein the other tyrosine kinases share homology with
`
`C481 S mutated Btk by having a serine residue Gncluding a homologous resisdue to BTK C481 S residue)
`that can form a covalent bond with the inhibitor.
`
`[0008] Further described herein are reversible inhibitors of C481 S mutated Btk.
`
`[0009] Further described herein are reversible inhibitors of other tyrosine kinases, wherein the other
`
`tyrosine kinases share homology with Btk.
`
`[0010] Also described herein are methods for synthesizing such reversible or irreversible inhibitors,
`
`methods for using such reversible or irreversible inhibitors in the treatment of diseases (including diseases
`
`wherein irreversible inhibition of Btk provides therapeutic benefit to a patient having the disease). Further
`
`described are pharmaceutical formulations that include a reversible or irreversible inhibitor of Btk.
`
`[0011] Thus, in one specific aspect, the present invention provides methods for preventing, treating or
`
`ameliorating in amammal a disease or condition that is causally related to the aberrant activity of a
`
`tyrosine kinase receptor in vivo, which comprises administering to the mammalan effective disease-
`
`treating or condition-treating amount of a compound according to Formula (1D having the structure:
`
`
`
`wherein:
`
` is aheterocyclic moiety that binds to the active site of a tyrosine kinase;
`
`1) Y is substituted or unsubstituted alkylene, heteroalkylene, arylene, heteroarylene,
`
`heterocycloalkylene, or cycloalkylene; and L, is NR,,; or
`
`h) Y is N containing substituted or unsubstituted heterocycloalkylene; and L, is a bond; provided
`
`that the L,-CN groupis attached to Y through the ring N;
`
`L, is abond or alkylene; and
`
`Rj, 1s H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or
`
`unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or
`
`unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a protecting group;
`
`or
`
`ametabolite, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof.
`
`[0012]
`
`In one embodiment, the tyrosine kinase receptor is Btk receptor.
`
`[0013]
`
`In onc embodiment, the active site is a cavity in which the compound or the moicty binds to the
`
`tyrosine kinase.
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`[0014]
`
`In one embodiment, the the disease or condition is an autoimmune disease, a heteroimmune
`
`disease, a cancer, mastocytosis, osteoporosis or bone resorption disorder, or an inflammatory disease.
`
`In anotheraspect, the present invention provides a compound according to Formula (1) having the
`[0015]
`structure:
`
`
`
`
`[|L
`
`4;—— CN
`
`wherein:
`
`@
`
` is aheterocyclic moiety that binds to the active site of a tyrosine kinase;
`
`1) Y is substituted or unsubstituted alkylene, heteroalkylene, arylene, heteroarylene,
`
`heterocycloalkylenc, or cycloalkylenc; and L; is NR,,; or
`
`h) Y is N containing substituted or unsubstituted heterocycloalkylene; and L, is a bond; provided
`
`that the L,-CN groupis attached to Y through the ring N;
`
`L, is abond or alkylene; and
`
`R,,1s H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or
`
`unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or
`
`unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a protecting group;
`
`or
`
`ametabolite, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof.
`
`
`wd wy
`ot Kang"
`
`ra
`
`we
`
`N~
`WJ
`
`/
`
`N
`Pp
`
`ok
`
`/
`
`\
`Nw
`Re LU ys
`
`we
`
`NH2
`N~ |
`
`=~
`N
`
`pe
`
`N
`
`N
`\
`Te
`
`oO
`
`2
`
`NH>
`N oo
`~~
`N
`
`|
`
`we
`Y—Ro
`N
`\
`we
`
`or
`
`NH2
`N on
`|
`
`ww
`N
`
`Wi
`8
`yN
`N
`\
`po
`
`,
`
`and wherein Wg is CR,, and R, is as described herein; and Rg is H, alkyl, CN,or halo.
`-3-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`[0017]
`
`In another particular embodiment, Wg is CR,; and R, is phenyl substituted with substituted or
`
`unsubstituted benzyl, substituted or unsubstituted phenoxy, substituted or unsubstituted phenthioxy, or
`
`substituted or unsubstituted phenylammo.
`
`[0018]
`
`In another aspect, the present invention provides pharmaceutical compositions comprising a
`
`therapeutically effective amount of a compound of Formula (I) and a pharmaceutically acceptable
`
`excipient.
`
`In one embodiment, the pharmaceutical composition comprising the compound of Formula (I)
`
`is formulated for aroute of administration selected from oral administration, parenteral administration,
`
`buccal administration, nasal administration, topical administration, or rectal administration.
`
`In another
`
`aspect is a method for treating an autoimmune disease or condition comprising administering to a patient
`
`in need a therapeutically effective amount of a compound of Formula (1).
`
`In one embodiment the
`
`autoimmune disease is selected from rheumatoid arthritis or lupus.
`
`In a further aspect is a method for
`
`treating a heteroimmunedisease or condition comprising administering to a patient in need a
`
`therapeutically effective amount of a compound of Formula (1).
`
`In yet another embodiment is a method
`
`for treating a cancer comprising administering to a patient in need a therapeutically effective amountof a
`
`compound of Formula (1).
`
`In one embodiment the cancer is a B-cell proliferative disorder.
`
`[0019]
`
`In another embodiment the B-cell proliferative disorder is diffuse large B cell lymphoma,
`
`follicular lymphoma or chronic lymphocytic leukemia.
`
`[0020]
`
`In yet a further aspect is a method for treating mastocytosis comprising administering to a patient
`
`in need a therapeutically effective amount of a compound of Formula (1).
`
`[0021]
`
`In another aspect, a method is provided for treating osteoporosis or bone resorption disorders
`
`comprising administering to a patient in need a therapeutically effective amount of a compound of
`
`Formula (1).
`
`[0022]
`
`In a further aspect, a method is provided for treating an inflammatory disease or condition
`
`comprising administering to a patient in need a therapeutically effective amount of a compound of
`
`Formula (1.
`
`[0023] Any combination of the groups described above for the various variables is contemplated herein.
`
`It is understood that substitucnts and substitution pattcrns on the compounds provided herein can be
`
`selected by one of ordinary skill in the art to provide compoundsthat are chemically stable and that can be
`
`synthesized by techniques knowninthe art, as well as those set forth herein.
`
`[0024]
`
`In afurther aspect, pharmaceutical compositions are provided which include a therapeutically
`
`effective amountof at least one of any of the compoundsherein, or a pharmaceutically acceptable salt,
`
`pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable
`
`solvate. In certain embodiments, compositions provided herein further include a pharmaceutically
`
`acceptable diluent, excipient and/or binder.
`
`[0025] Pharmaceutical compositions formulated for administration by an appropriate route and means
`
`containing effective concentrations of one or more of the compounds provided herein, or pharmaceutically
`
`effective derivatives thereof, that deliver amounts effective for the treatment, prevention, or amelioration
`
`of one or more symptoms of dieases, disorders or conditions that are modulated or otherwise affected by
`
`tyrosine kinase activity, or in which tyrosine kinase activity is implicated, are provided. The effective
`-4-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`amounts and concentrations are effective for ameliorating any of the symptoms of any of the diseases,
`disorders or conditions disclosed herein.
`
`[0026]
`
`In certain embodiments, provided herein is a pharmaceutical composition containing:
`
`1) a
`
`physiologically acceptable carrier, diluent, and/or excipient; and ii) one or more compounds provided
`herein.
`
`[0027]
`
`In one aspect, provided herein are methodsfor treating a patient by administering a compound
`
`provided herein. In some embodiments, provided herein is a method of inhibiting the activity of tyrsome
`
`kinase(s), such as Btk, or of treating a disease, disorder, or condition, which would benefit from inhibition
`
`of tyrosine kinase(s), such as Btk, in a patient, which includes administering to the patient a
`
`therapeutically effective amount of at least one of any of the compounds herein, or pharmaceutically
`
`acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or
`
`pharmaceutically acceptable solvate.
`
`[0028]
`
`In another aspect, provided herein is the use of a compound disclosed herein for inhibiting
`
`Bruton's tyrosine kinase (Btk) activity or for the treatment of a disease, disorder, or condition, which
`
`would benefit from inhibition of Bruton's tyrosine kinase (Btk) activity.
`
`[0029]
`
`In some embodiments, compounds provided herein are administered to a human.
`
`[0030]
`
`In some embodiments, compounds provided herein are orally administered.
`
`[0031]
`
`In other embodiments, compounds provided herein are used for the formulation of a medicament
`
`for the inhibition of tyrosine kinase activity.
`
`In some other embodiments, compounds provided herein are
`
`used for the formulation of a medicamentfor the inhibition of Bruton's tyrosine kinase (Btk) activity.
`
`[0032] Articles of manufacture including packaging material, a compound or composition or
`
`pharmaceutically acceptable derivative thereof provided herein, whichis effective for inhibiting the
`
`activity of tyrosine kinase(s), such as Btk, within the packaging material, and a label that indicates that the
`
`compound or composition, or pharmaceutically acceptable salt, pharmaceutically active metabolite,
`
`pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is used for inhibiting
`
`the activity of tyrosine kinase(s), such as Btk, are provided.
`
`[0033]
`
`In afurther aspect, provided hercin is a method for inhibiting Bruton's tyrosine kinase in a subject
`
`in need thereof by administering to the subject thereof a composition containing a therapeutically effective
`
`amountof at least one compound having the structure of Formula (D.
`
`In some embodiments, the subject
`
`in need is suffering from an autoimmunedisease, e.g., inflammatory bowel disease, arthritis, lupus,
`
`rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes,
`
`myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease Sjogren's syndrome, multiple
`
`sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-
`
`myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia,
`
`autoimmunehepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura,
`
`optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, Lemporal
`
`arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis,
`
`Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia,
`
`scleroderma, or vulvodynia.
`
`-5-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`[0034]
`
`In other embodiments, the subject in need is suffering from a heteroimmune condition or disease,
`
`e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity,
`
`allergic conjunctivitis, allergic rhinitis, or atopic dermatitis.
`
`[0035]
`
`In certain embodiments, the subject in need is suffering from an inflammatory disease, e.g.,
`
`asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis,
`
`colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis,
`
`endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis,
`
`gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis,
`
`myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis,
`
`pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis,
`
`salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis.
`
`[0036]
`
`In further embodiments, the subject in need is suffering from a cancer. In one embodiment, the
`
`cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma,follicular lymphoma, chronic
`
`lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia,
`
`lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma,
`
`plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B
`
`cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B
`
`cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, or lymphomatoid
`
`granulomatosis. In some embodiments, where the subject is suffering from a cancer, an anti-cancer agent
`
`is administered to the subject in addition to one of the above-mentioned compounds.
`
`In one embodiment,
`
`the anti-cancer agentis an inhibitor of mitogen-activated protein kinase signaling, e.g., UV0126, PD98059,
`
`PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannm, or
`LY294002.
`
`[0037]
`
`In further embodiments, the subject in need is suffering from a thromboembolic disorder, e.g.,
`
`myocardial infarct, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion
`
`after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral
`
`artcrial occlusive disorder, pulmonary cmbolism, or decp venous thrombosis.
`
`[0038]
`
`In afurther aspect, provided herein is a method for treating an autoimmunedisease by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amount of
`
`at least one compound having the structure of Formula Formula (D, (Ila)-dIp, (la)-dII), (Va)-dVp,
`
`(Va)-(Vf), (Vla)-CVIN, CVila)-(VII), (VHIa)-CVIIIf), (7Xa)-(EXf), CXa)-CXf), CXTa)-CXTf), (XTla)-CcT),
`
`(X1lla)-CXT),
`
`(X1Va)-CXIVA), (XVa)-(XVE), OCVIa)-CXVID, (XVITa)-(XVITA), OCVIa)- XVII),
`
`(X)X%a)-(X1Xf), (XXa)-(XXf), (XXla)-(XXI1f), or CXXTla)-C<XIIf).
`
`In one embodiment, the autoimmune
`
`disease is arthritis. In another embodiment, the autoimmunedisease is lupus. In some embodiments, the
`
`autoimmunedisease is inflammatory bowel disease (including Crohn's disease and ulcerative colitis),
`
`rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Sull's disease, juvenile arthritis, lupus, diabetes,
`
`myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease Sjogren's syndrome, multiple
`
`sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-
`
`myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia,
`-6-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura,
`
`optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal
`
`arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis,
`
`Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia,
`
`scleroderma, or vulvodynia.
`
`[0039]
`
`In afurther aspect, provided herein is a method for treating a heteroimmune condition or disease
`
`by administering to a subject in need thereof a composition containing a therapeutically effective amount
`
`of at least one compound having the structure of (D, (la)-CIIf), (la)-dUf, (Va)-dVf), (Va)-(Vf), (Vla)-
`
`(VID, CVila)-CVILD, ~CVilla)-CVOID, (xa)-dxD, (Xa)-CXD, CXla)-CXID, CXlla)-CXIID, Cxla)-CXTI),
`
`(x1Va)-CXIVf),
`
`(XVa)-CXVf), CXVIa)-CXVIN, CxVIa)-CXVITN, OsVIa)-CXVITA, ~CXxEXa)-CXTxf),
`
`(XXa)-(XXf), CXXTa)-CXXIAF, or COCXTIa)-CCXTIA).
`
`In some embodiments, the heteroimmune conditiom
`
`or disease is graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I
`
`hypersensitivity, allergic conjunctivitis, allergic rhinitis, or atopic dermatitis.
`
`[0040]
`
`In a further aspect, provided herein is a method for treating an inflammatory disease by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amount of
`
`at least one compound having the structure of Formula (1, (Ma)-dT, (lla)-dIIP), (Va)-dVf), CVa)-CVA,
`
`(Vla)-C(VIf), (Vlla)-CVIIf), CVUla)-CVOIf, doxa)-(xf), (Xa)-Cxf), (xla)-CxIf), Cxlla)-CXIIf), Cxla)-
`
`CX, C1Va)-COTIVA), OCVa)-XVI), OOVIa)-(XVIf), OVIa)-XVOf), OCVIa)-OOVOTA,
`
`(XTXa)-
`
`(XIX), (XXa)-(XXE), OCXTa)-COCXTA), or CXXTa)-CXILf).
`
`In some embodiments, the inflammatory
`
`disease is asthma, inflammatory bowel disease (including Crohn's disease and ulcerative colitis),
`
`appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis,
`
`conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis,
`
`endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis,
`
`gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis,
`
`myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis,
`
`pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis,
`
`salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uvcitis, vaginitis, vasculitis, or vulvitis.
`
`[0041]
`
`In yet another aspect, provided herein is a method for treating a cancer by administering to a
`
`subject in need thereof a composition containing a therapeutically effective amountof at least one
`
`compound having the structure of Formula (1, (a)-(ITf), (a)-(IIIf), (Wa)-(IVf, (Va)-(Vf), (Vla)-CVID,
`
`(Vila)-CVIf), CVilla)-CVINA,
`
`(xXa)-(Xf), (Xa)-CXf), CXla)-CXT, Cclla)-OIH, Ccla)-CXTTf, CdVa)-
`
`(XIVf), (XVa)-(XVE), (XVIa)-COVIF), (XV Ia)-CXVOf), CXVITTa)-COVITED), CXXa)-CXTX£),
`
`(XX a)-(XXf),
`
`(XXTa)-(XXIf), or (XXTla)-(XXII).
`
`In one embodiment, the cancer is a B-cell proliferative disorder, e.g.,
`
`diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic
`
`lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/W aldenstrom
`
`macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal
`
`marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma,
`
`mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion
`
`lymphoma, burkitt lymphoma/leukemia, or lymphomatoid granulomatosis. In some embodiments, where
`-7-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`the subject is suffering from a cancer, an anti-cancer agent is administered to the subject in addition to one
`
`of the above-mentioned compounds. In one embodiment, the anti-cancer agent is an inhibitor of mitogen-
`
`activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARR Y-142886,
`
`$B239063, SP600125, BAY 43-9006, wortmannm, or LY294002.
`
`[0042]
`
`In another aspect, provided herein is a method for treating a thromboembolic disorder by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amountof
`
`at least one compoundhaving the structure of Formula (I, (Ila)-dIf), (la)-dHf), (7Va)-dVf), (Va)-(Vf),
`
`(Vla)-CVIf), CVila)-(VII), (Villa)-CVTIf), (-Xa)-(-Xf), CXa)-(Xf), CXla)-CXT, Cxla)-CXTI), CXllla)-
`
`CXUIA, CX)Va)-CXTV#), CXVa)-(XV1), CXVIa)-(XVIN, CXVIa)-CXVO), CXVIa)-CXVOI), CXLXa)-
`
`CXTXf), CXXa)-COX), CXXKTa)-CXXIN, or CXXTIa)-CXXIIf).
`
`In some embodiments, the thromboembolic
`
`disorder is myocardial infarct, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty,
`
`reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia,
`
`a peripheral arterial occlusive disorder, pulmonary embolism, or deep venous thrombosis.
`
`[0043]
`
`In afurther aspect, provided herein is a method for treating an autoimmunedisease by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amount of a
`
`compound that forms a covalent bond with Bruton's tyrosine kinase.
`
`In one embodiment, the compound
`
`forms a covalent bound with the activated form of Bruton's tyrosine kinase. In further or alternative
`
`embodiments, the compound irreversibly inhibits the Bruton's tyrosine kinase to which it is covalently
`
`bound.
`
`In a further or alternative embodiment, the compound forms a covalent bond with a cysteine
`
`residue on Bruton's tyrosine kinase.
`
`[0044]
`
`In a further aspect, provided herein is a method for treating a heteroimmune condition or disease
`
`by administering to a subject in need thereof a composition containing a therapeutically effective amount
`
`of a compound that forms a covalent bond with Bruton's tyrosine kinase. In one embodiment, the
`
`compound forms a covalent bound with the activated form of Bruton's tyrosine kinase. In further or
`
`alternative embodiments, the compoundirreversibly inhibits the Bruton’s tyrosine kinase to whichit is
`
`covalently bound.
`
`In a further or alternative embodiment, the compound forms a covalent bond with a
`
`cystcine residuc on Bruton's tyrosine kinasc.
`
`[0045]
`
`In a further aspect, provided herein is a method for treating an inflammatory disease by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amountof a
`
`compoundthat forms a covalent bond with Bruton's tyrosine kinase. In one embodiment, the compound
`
`forms a covalent bound with the activated form of Bruton's tyrosine kinase. In further or alternative
`
`embodiments, the compound irreversibly inhibits the Bruton's tyrosine kinase to which it is covalently
`
`bound.
`
`In afurther or alternative embodiment, the compound forms a covalent bond with a cysteine
`
`residue on Bruton's tyrosine kinase. In yet another aspect, provided herein is a method for treating a
`
`cancer by administering to a subject in need thereof a composition containing a therapeutically effective
`
`amount of a compound that forms a covalent bond with Bruton's tyrosine kinase. In one embodiment, the
`
`compound forms a covalent bound with the activated form of Bruton's tyrosine kinase. In further or
`
`alternative embodiments, the compound irreversibly inhibits the Bruton’s tyrosine kinase to whichit is
`
`covalently bound. In a further or alternative embodiment, the compound forms a covalent bond with a
`-8-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`cysteine residue on Bruton's tyrosine kinase.
`
`[0046]
`
`In another aspect, provided herein is a method for treating a thromboembolic disorder by
`
`administering to a subject in need thereof a composition containing a therapeutically effective amount of a
`
`compound that forms a covalent bond with Bruton's tyrosine kinase. In one embodiment, the compound
`
`forms a covalent bound with the activated form of Bruton's tyrosine kinase. In further or alternative
`
`embodiments, the compound irreversibly inhibits the Bruton's tyrosine kinase to which it is covalently
`
`bound. In a further or alternative embodiment, the compound forms a covalent bond with a cysteine
`
`residue on Bruton's tyrosine kinase.
`
`[0047]
`
`In another aspect are methods for modulating, including irreversibly inhibiting the activity of Btk
`
`or other tyrosine kinases, wherein the other tyrosine kinases share homology with Btk by having a
`
`cysteine residue (including a Cys 481 residue) that can form a covalent bond with at least one irreversible
`
`inhibitor described herein, in a mammal comprising administering to the mammal at least once an
`
`effective amount ofat least one compound having the structure of Formula (D, Cla)-d1, Clla)-dUf),
`
`(Va)-dVf), (Va)-(V, CVla)-CVID, CVla)-CVIIA), CVilla)-CVTIA), (-Xa)-(2Xf), (Xa)-CXf), CXla)-CXT£),
`
`CXlla)-CXTI, CXIa)-CXTA, CXTWa)-(XTVA), (XVa)-CXVH), CXVIa)-XVID, CXVIIa)-COVITD, OXVIITa)-
`
`CXVTTTA, CX Xa)-CXTX1), COXa)-CXXD), CXOXKTa)-CXXTP) or CX®KTTa)-CXXTIP). Tn another aspect are
`
`methods for modulating, including including reversibly or irreversibly inhibiting, the activity of Btk in a
`
`mammal comprising administering to the mammal at least once an effective amount of at least one
`
`compound having the structure of Formula (1), dla)-dIf), Ula)-dII, (Va)-dV), (Va)-(V, (Vla)-CVID,
`
`(Vila)-(VIIf), (Villa)-CVIIA, (Xa)-(2xf), (Xa)-CXf), CXla)-CXTf), CXIla)-CXTIA), Cxia)-CXTO), Cx1Va)-
`
`CX1Vf), (XVa)-(XV£), CXVIa)-CXVID, CXVIla)-CXVIL), (XVIa)-CXVOIA), (XTXa)-(XTXf), (XKa)-CxXf),
`
`(XXIa)-CXXIf), or (xXTla)-COCXTIf).
`
`In another aspect are methods for treating Btk-dependent or Btk
`
`mediated conditions or diseases, comprising administering to the mammalat least once an effective
`
`amountof at least one compound havingthe structure of Formula (D, dla)-dIf, dlla)-d0N, (Va)-dvp,
`
`(Va)-(Vf), (Vla)-CVID), CVila)-(VIIf), CVilla)-C(VI), (Xa)-(-Xf), (Xa)-CXf), CXla)-CXTD, CxTla)-CXTIA),
`
`(Xilla)-CSMT, xlVa)-CXIVi), (Va)-(XVE), CXVIa)-CXVID, CXVIa)-CXVID), (XVIa)-(XVITA),
`
`CX1X%a)-CXTX#), OXXa)-OOXK), CXXTa)-COCXTA), or CXXTIa)-CCXTL).
`
`[0048]
`
`In another aspect are methods for treating inflammation comprising administering to the mammal
`
`al least once an effective amountof al least one compound having the structure of Formula (D, (a)-dIf,
`
`(ila)-d0f), (Va)-dVfi), (Va)-(Vf), (Vla)-CVIN), CVila)-CVIID,
`
`(VHIa)-(VIIf), (Xa)-(Exf), CXa)-Cxf),
`
`(Xla)-CXTf), CXla)-CCTI, ~Cxila)-CXTIA), CXTVa)-CXTVf), CXVa)-CXV), CXVIa)-CXVIf), (XVIIa)-
`
`(XVIIf), OSVIITa)-CXVITID, CX1Xa)-CXTXA), (XXa)-OOXKT), OXXTa)-OCXTA), or OCKTIa)-OCXIIf).
`
`[0049] A further aspect are methods for the treatment of cancer comprising administering to the mammal
`
`at least once an effective amountof at least one compound having the structure of Formula (1D, dla)-dIf,
`
`(la)-d0f), (Va)-(Vif), (Va)-(Vf), (Vla)-CVID, CVla)-(VHf, (VIlla)-CVOIf,
`
`(2Xa)-(Zxf), (Xa)-CXf),
`
`(Xla)-CXTN, CXTla)-CXTID, ~CXM1a)-CXTITN, ~CXTVa)-CXTVI), CXVa)-(XVI, CXVIa)-CXVIN, CXVTTa)-
`
`CXVIIf), CSVIIJa)-CXVIIA), CxTXa)-(XTXf), (XXa)-Ockt), CXXTa)-OCXT£), or OCKTIa)-OCXIIf). The type
`
`of cancer may include, but is not limited to, pancreatic cancer and other solid or hematological tumors.
`
`[0050]
`
`In another aspect are methodsfor treating respiratory diseases comprising administering to the
`-9-
`
`

`

`WO 2016/019237
`
`PCT/US2015/043102
`
`mammal at least once an effective amountof at least one compound havingthe structure of Formula (1),
`
`(Ila)-dIf), dHa)-dIIf), (VWa)-dVf), CVa)-(Vf), CVla)-CVIf), (Vla)-CVIIf), (VHIa)-CVHIf), (TXa)-Cxf),
`
`(Xa)-(Xf), (Xla)-CXTf), CXTla)-CXTIf), CXMa)-CXTMf), CXTWa)-CXTV£), CXVa)-CX VP), CXVTa)-(XVIF),
`
`(XVila)-CXVIIf), OXVIIa)-CXVITIF), CXTXa)-CXTX£), OCKa)-OCXf), (XXTa)-CCKI£), or OCKTIa)-OCXTf).
`
`In a further embodiment of this aspect, the respiratory disease is asthma.
`
`In a further embodimento

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket